Lutathera
Evidence Grade A — Regulatory approved. 18 published studies. 85 registered clinical trials.
Loading...
Lutetium Lu-177 dotatate (sold as Lutathera) is a targeted radiation treatment for neuroendocrine tumours — rare cancers, often found in the digestive system, that display specific receptors on their surface. It works like a guided missile: a tumour-seeking peptide carries a radioactive atom directly to the cancer cells, destroying them from within while largely sparing surrounding tissue. It is given as four intravenous infusions, eight weeks apart.
18 published studies: 10 human, 0 animal, 0 in-vitro, 5 reviews
Lutathera is marketed by Novartis (approved January 2018) for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults. It is administered as four intravenous infusions given every 8 weeks.
The NETTER-1 trial showed dramatic results: at 20 months, 65% of patients on Lutathera had not progressed compared to only 11% on high-dose octreotide alone. Patients must have somatostatin receptor-positive tumours confirmed by nuclear imaging before treatment. The main risks are bone marrow suppression (affecting blood cell production) and kidney toxicity. Lutathera established peptide receptor radionuclide therapy as a mainstream cancer treatment approach and paved the way for similar radiopharmaceuticals in other cancers.
Neuroendocrine tumour cells abundantly display somatostatin receptors on their surface. Lutathera consists of a somatostatin-like peptide (that finds and binds to these receptors) attached via a chemical linker to a radioactive atom (lutetium-177). Once the peptide docks onto the tumour cell's receptor, the whole complex is pulled inside the cell. The lutetium-177 then emits beta radiation that damages the tumour cell's DNA, causing it to die. The radiation penetrates only about 2mm of tissue, limiting collateral damage to surrounding healthy tissue.
The NETTER-1 trial showed dramatic results: at 20 months, 65% of patients on Lutathera had not progressed compared to only 11% on high-dose octreotide alone. This established peptide receptor radionuclide therapy as a mainstream cancer treatment and paved the way for similar radiopharmaceuticals targeting other cancers. Patients must have their tumours confirmed as somatostatin receptor-positive by a nuclear imaging scan before treatment. The main risks are bone marrow suppression (affecting blood cell production) and kidney toxicity, and there is a small long-term risk (approximately 2%) of secondary blood cancers (MDS/AML). A follow-up trial (NETTER-2) has evaluated use earlier in the treatment course with positive results, and combination approaches with other cancer drugs are in active study.
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
EMA Marketing Authorisation
FDA ORIG 1
FDA SUPPL 10
FDA SUPPL 1
FDA SUPPL 20
FDA SUPPL 19
FDA SUPPL 23
FDA SUPPL 26
FDA SUPPL 31
FDA SUPPL 32
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
